Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Phynova Group Ltd
- Study ID
- NCT07333885
- Status
- Recruiting
Conditions
- Glycemic Response
- Menopause Symptoms
Eligibility Criteria
- Sex
- FEMALE
- Age
- 40 Years - 60 Years
- Healthy Volunteers
- Accepted
Interventions
- Reducose® (Mulberry leaf extract) — DIETARY_SUPPLEMENTReducose® proprietary mulberry leaf extract, 250mg, 2/day with meals
- Placebo — DIETARY_SUPPLEMENTPlacebo matching capsules, Microcrystalline Cellulose
Study Details
The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.
Key Dates
- Start date
- Dec 12, 2025
- Status verified
- Jan 2026
- Primary completion
- Jun 30, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Reducose® Mulberry Leaf Extract
- Placebo Comparator: Matching Placebo
Primary Outcome Measure
Glycemic response following test meal [ Time Frame: Baseline and end-of-study test meals (Days 10, 14, and 98). ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| People Science | Los Angeles | California | 90034 |
Find similar trials in Los Angeles, CA
By research site